COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 1
From BugSigDB
Reviewed Marked as Reviewed by ChiomaBlessing on 2024-2-15
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Breast , Milk Mamma,Mammary part of chest,Mammary region,Breast,breast,Mammary gland milk,Milk,milk
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Response to vaccine , Timepoint Response to vaccine,response to vaccine,Timepoint,timepoint
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Mothers at pre-vaccination timepoint
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Mothers at post vaccination timepoints
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Breastfeeding mothers at post vaccination timepoints; one week post-first dose, one week post second-dose, one month post-second dose.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 44
- Group 1 sample size Number of subjects in the case (exposed) group
- 44
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- None
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 1.5
Signature 1
Reviewed Marked as Reviewed by ChiomaBlessing on 2024-2-15
Source: figure 1g
Description: The most differentially abundant taxa in mothers throughout all post-vaccination timepoints; at one week post-first dose, one week post-second dose and one month post-second dose.
Abundance in Group 1: increased abundance in Mothers at post vaccination timepoints
| NCBI | Quality Control | Links |
|---|---|---|
| Acinetobacter ursingii | ||
| Roseomonas gilardii | ||
| unclassified Brevundimonas | ||
| unclassified Gordonia (in: high G+C Gram-positive bacteria) | ||
| unclassified Paracoccaceae |
Revision editor(s): Folakunmi
Signature 2
Reviewed Marked as Reviewed by ChiomaBlessing on 2024-2-15
Source: figure 1g
Description: The most differentially abundant taxa in mothers throughout all post-vaccination timepoints; at one week post-first dose, one week post-second dose and one month post-second dose.
Abundance in Group 1: decreased abundance in Mothers at post vaccination timepoints
| NCBI | Quality Control | Links |
|---|---|---|
| Helicobacter rodentium | ||
| unclassified Allobaculum | ||
| unclassified Muribaculaceae | ||
| unclassified Ralstonia | ||
| unclassified Turicibacter |
Revision editor(s): Folakunmi
